Side-by-side · Research reference

GHRP-2vsVilon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED15/42 cited

BAnimal-StrongHUMAN-REVIEWED13/49 cited

GHRP-2

Hexapeptide GHRP · Phase 2 (clinical diagnostic)

100–300 mcgPer doseBowers 1990

Phase 2Evidence levelBowers 1990 Sigalos 2018

~30 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

Vilon

Khavinson Bioregulator · Dipeptide

2 AADipeptide

T-helperStimulatesLinkova 2011

MouseModel basisKhavinson 2002

Literature lacks standardised clinical route

01Mechanism of Action

Parameter

GHRP-2

Vilon

Primary target

Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990

Immune cell differentiation pathways, chromatin modification

Pathway

GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002

Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)

Downstream effect

Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002

Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011 Khavinson 2002 Lezhava 2023

Feedback intact?

Yes, with somatostatin feedback active

Unknown — no HPA/HPG axis data

Origin

Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990

Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997

Antibody development

—

02Dosage Protocols

Parameter

GHRP-2

Vilon

Standard dose

100–300 mcg per injectionBowers 1990

No clinical standard — literature lacks human dosing

Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.

Frequency

1–3× per day

Unknown — literature does not specify chronic administration protocols

Lower / starter dose

50 mcg per dose

—

Evidence basis

Phase 2 + clinical diagnostic useBowers 1990

Mouse / in vitro only

Duration

8–12 weeks on / 4 off (anecdotal)

Not characterised in humans

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep + fasted preferred

—

Half-life

~30 minMalagón 1999

Not published — dipeptides typically <10 min plasma t½

Animal model dose

—

In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)

Not translatable to human mg/kg without pharmacokinetic data.

Route

—

Likely SQ or oral (Khavinson school uses both); no published ROA validation

04Side Effects & Safety

Parameter

GHRP-2

Vilon

Cortisol elevation

Mild but measurableBowers 1990

—

Prolactin elevation

Mild but measurable

—

Hunger

Strong appetite increase

—

Injection site reaction

Mild erythema

—

IGF-1 elevation

Strong; monitor with chronic high-dose use

—

Cancer risk

Contraindicated in active malignancy

—

Pregnancy / OB

Avoid

—

Human safety data

—

Absent from PubMed-indexed literature

Theoretical risk

—

Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)

Antibody formation

—

Not reported; dipeptides generally low immunogenicity

Animal models

—

No adverse effects noted in mouse thymocyte or pineal lymphoid cultures

Absolute Contraindications

GHRP-2

·Active malignancy
·Pregnancy / breastfeeding

Vilon

·Active autoimmune disease (theoretical — no clinical data)

Relative Contraindications

GHRP-2

·Untreated diabetes

Vilon

·Pregnancy / lactation (no safety data)
·Acute infection with cytokine storm risk (immune modulation unknown)

05Administration Protocol

Parameter

GHRP-2

Vilon

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

2. Injection site

SQ — abdomen or thigh. Rotate sites.

Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

3. Timing

Pre-sleep + fasted preferred.

Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

5. Needle

29–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

GHRP-2

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

GHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.

GHRP-2: 100–200 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: High-amplitude GH pulse, body composition

Bowers 1990 Teichman 2006

Vilon

+ Epitalon

Moderate

View Epitalon →

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Vilon: Empirical — no standard
Epitalon: Empirical — often 10 mg cycles
Frequency: Sequential or concurrent (literature ambiguous)
Primary benefit: Multi-system aging modulation (immune + pineal/circadian)

+ Thymalin

Weak

View Thymalin →

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Vilon: No standard
Thymalin: 10–100 mg IM (polypeptide complex)
Primary benefit: Redundant — both target T-cell differentiation

Morozov 1997 Khavinson 2020